Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04214873Not ApplicableCompleted

Evaluation of the Effectiveness of the PiQo4 System for Reduction of Infra-orbital Pigmentation

Role: lead

NCT04539561Not ApplicableUnknown

Evaluation of the Efficacy and Safety of PiQo4 for the Treatment of Hand Pigmentation Using 1064nm PSL and 532nm PSL

Role: lead

NCT03565146Not ApplicableCompleted

Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions

Role: lead

NCT03565341Not ApplicableCompleted

Efficacy and Safety of PiQo4 Device for Treatment of Melasma

Role: lead

NCT03322475Not ApplicableUnknown

Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation

Role: lead

All 5 trials loaded